A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

November 2, 2026 updated by: IDEAYA Biosciences

An Open Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of IDE574 as Monotherapy in Locally Advanced or Metastatic Solid Tumors and as Combination Therapy With Fulvestrant in Locally Advanced or Metastatic Cancer

IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.

The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of IDE574 as monotherapy in participants with locally advanced or metastatic solid tumors and as combination therapy with fulvestrant in participants with advanced or metastatic cancer.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Part 1 - Monotherapy Dose Escalation and Expansion:

Part 1A - Monotherapy Dose Escalation Part 1A will evaluate increasing doses of IDE574 to assess safety, tolerability and to determine dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD) or the recommended dose for expansion (RDE) in subjects with advanced or metastatic cancer.

Part 1B - Monotherapy Dose Expansion Part 1B will evaluate in ER+ HER2- advanced or metastatic cancer at one RDE determined from Part 1A or the MTD.

Part 1C - Exploratory Food Effect Sub-study

Part 2 - Combination Dose Escalation and Expansion

Part 2A - IDE574 Combination Therapy with Fulvestrant Dose Escalation Part 2A will evaluate participants with advanced or metastatic cancer with escalating doses of IDE574 in combination with fulvestrant to assess safety, tolerability and to determine DLTs, MTD or RDE.

Part 2B - IDE574 Combination Therapy with Fulvestrant Dose Expansion Part 2B will randomly assign participants with advanced or metastatic cancer to dose levels selected from Part 2A

Study Type

Interventional

Enrollment (Estimated)

155

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • K'alak'i T'bilisi
      • Batumi, K'alak'i T'bilisi, Georgia, 6000
        • Recruiting
        • High Technology Hospital MedCenter Ltd
        • Principal Investigator:
          • Tamta Makharadze, MD
        • Contact:
      • Tbilisi, K'alak'i T'bilisi, Georgia, 114
        • Recruiting
        • Pineo Medical Ecosystem
        • Contact:
        • Principal Investigator:
          • Mziuri Zakaraia, MD
      • Tbilisi, K'alak'i T'bilisi, Georgia, 112
        • Active, not recruiting
        • LLC ARENSIA Exploratory Medicine
      • Tbilisi, K'alak'i T'bilisi, Georgia, 144
        • Active, not recruiting
        • Geo Hospitals Multiprofile Medical Center Tbilisi
      • Tbilisi, K'alak'i T'bilisi, Georgia, 186
        • Active, not recruiting
        • LLC Caucasus Medical Centre
    • California
      • Santa Monica, California, United States, 90404-2095
        • Active, not recruiting
        • UCLA - Parkside Cancer Center
    • Connecticut
      • New Haven, Connecticut, United States, 06510-3206
        • Recruiting
        • Yale School of Medicine - Cedar Street
        • Principal Investigator:
          • Patricia LoRusso, MD
        • Contact:
    • Florida
      • Plantation, Florida, United States, 33322
        • Recruiting
        • Florida Clinical Trials Group
        • Principal Investigator:
          • Harshad Amin, MD
        • Contact:
    • Georgia
      • Atlanta, Georgia, United States, 30322-1013
        • Recruiting
        • Winship Cancer Institute, Emory University
        • Principal Investigator:
          • Shipra Gandhi, MD
        • Contact:
    • Missouri
      • St Louis, Missouri, United States, 63110-1010
        • Recruiting
        • Washington University - Siteman Cancer Center
        • Principal Investigator:
          • Faisal Fa'ak, MD
        • Contact:
    • New Jersey
      • East Brunswick, New Jersey, United States, 08816
        • Recruiting
        • START Astera, LLC
        • Principal Investigator:
          • Bruno Fang, MD
        • Contact:
    • New York
      • Lake Success, New York, United States, 11042
        • Recruiting
        • START New York Long Island, LLC
        • Principal Investigator:
          • Geraldine O'Sullivan Coyne, MD
        • Contact:
      • New York, New York, United States, 10032-3729
        • Active, not recruiting
        • Columbia University Medical Center -161 Fort Washington
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Recruiting
        • SCRI Oncology Partners - PPDS
        • Principal Investigator:
          • Sarah Premji, MD
        • Contact:
    • Texas
      • Austin, Texas, United States, 78758
      • Dallas, Texas, United States, 75039
      • Fort Worth, Texas, United States, 76104
        • Recruiting
        • START Dallas Fort Worth, LLC
        • Principal Investigator:
          • Henry Xiong, MD
        • Contact:
      • Houston, Texas, United States, 77030-4009
        • Recruiting
        • MD Anderson Cancer Center
        • Principal Investigator:
          • Timothy Yap, MD
        • Contact:
      • Houston, Texas, United States, 77054
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • NEXT Texas LLC - San Antonio
        • Principal Investigator:
          • David Sommerhalder, MD
        • Contact:
      • San Antonio, Texas, United States, 78229
        • Recruiting
        • Start San Antonio, LLC
        • Principal Investigator:
          • Amita Patnaik, MD
        • Contact:
    • Utah
      • West Valley City, Utah, United States, 84119
        • Recruiting
        • START Mountain Region, LLC
        • Principal Investigator:
          • William McKean, MD
        • Contact:
    • Virginia
      • Fairfax, Virginia, United States, 22031

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Archival Tissue sample for testing

  • Part 1A - Participants with advanced or metastatic cancer who have progressed on/after standard of care therapy or are intolerant to additional effective therapies.
  • Female participants with cancer considered to be of childbearing potential (or have tubal ligations only) must be willing to undergo medically induced menopause (Parts 2A and B only)
  • Female participants of nonchildbearing potential with cancer must meet at least 1 of the following criteria: Age ≥ 60 years or age <60 years with absence of menstruation for at least 12 months, or had prior removal of both ovaries
  • Have Eastern Cooperative Oncology Group performance status (ECOG PS) of ≤1.
  • Have adequate bone marrow, renal and liver function.
  • Life expectancy of >3 months
  • Able to safely administer and retain orally administered study treatment
  • Able to comply with contraceptive/barrier requirements

Key Exclusion Criteria:

  • Known symptomatic brain metastases or leptomeningeal metastasis
  • Known primary CNS malignancy and any other malignancies within 2 years prior to the first dose with the exception of adequately treated localized tumor.
  • Have impairment of GI function or GI disease that may significantly alter the absorption of IDE574.
  • Have active liver or biliary disease.
  • Have active, uncontrolled bacterial, fungal, or viral infection
  • Have clinically significant cardiac abnormalities and/or blood clotting events within 6 months before the first dose
  • If participants had adverse reactions to previous experimental antitumor treatment that have not recovered to Grade ≤ 1
  • Prior irradiation to >25% of the bone marrow.
  • Known or suspected hypersensitivity to IDE574/excipients or components (Parts 1 & 2) or fulvestrant/excipients or components (Part 2 only)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Monotherapy Dose Escalation (Part 1A)

Participants with the appropriate tumor types will be treated with escalating doses of IDE574

IDE574

Experimental: Monotherapy Dose Expansion (Part 1B)

Participants with advanced or metastatic cancer will be treated using the RDE or MTD of IDE574

IDE574

Experimental: Combination Dose Escalation (Part 2A) IDE574 + Fulvestrant

Participants with advanced or metastatic cancer will be treated with escalating doses of IDE574 in combination with fulvestrant

IDE574

Fulvestrant Injection

Experimental: Combination Dose Expansion (Part 2B)

Participants with advanced or metastatic cancer will be randomly assigned to doses of IDE574 + Fulvestrant

IDE574

Fulvestrant Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation
Time Frame: Following the first dose of IDE574

incidence of DLT; incidence and severity of AEs/serious adverse events (SAEs) graded based on CTCAE V6.0

Following the first dose of IDE574
Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs
Time Frame: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1
Time Frame: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
To evaluate anti-tumor activity of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.
Time Frame: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT
Time Frame: total study duration

Incidence of DLT; incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the incidence and severity of AEs/SAEs
Time Frame: total study duration

Incidence and severity of AEs/SAEs graded based on CTCAE V6.0

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on the ORR per RECIST version 1.1
Time Frame: total study duration

Objective Response Rate (ORR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration
Anti-tumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on DOR per RECIST version 1.1.
Time Frame: total study duration

Duration of response (DOR) per RECIST version 1.1 will be calculated based on the proportion of participants with confirmed Complete Response or Partial Response

total study duration

Secondary Outcome Measures

Outcome Measure
Time Frame
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on the ORR per RECIST version 1.1
Time Frame: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on DOR per RECIST version 1.1.
Time Frame: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Clinical Benefit Rate (CBR)
Time Frame: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in Part 1A Monotherapy Dose Escalation based on Disease control rate
Time Frame: total study duration
total study duration
Evaluate the pharmacokinetics (PK) of IDE574 in Part 1A Monotherapy Dose Escalation
Time Frame: total study duration
total study duration
Evaluate the PK of IDE574 in Part 1B Monotherapy Dose Expansion
Time Frame: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion
Time Frame: total study duration
total study duration
Evaluate antitumor activity of IDE574 in Part 1B Monotherapy Dose Expansion based on DCR for other solid tumor types
Time Frame: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on ORR per RECIST version 1.1
Time Frame: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on DOR per RECIST version 1.1
Time Frame: total study duration
total study duration
Evaluate the preliminary antitumor activity of IDE574 in combination with Fulvestrant Part 2A Combination Dose Escalation based on CBR per RECIST version 1.1
Time Frame: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2A Combination Dose Escalation
Time Frame: total study duration
total study duration
Evaluate antitumor activity of IDE574 in combination with Fulvestrant in Part 2B Combination Dose Expansion based on CBR per RECIST version 1.1
Time Frame: total study duration
total study duration
Evaluate the PK of IDE574 in Part 2B Combination Dose Expansion
Time Frame: total study duration
total study duration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 17, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

January 31, 2030

Study Registration Dates

First Submitted

April 1, 2026

First Submitted That Met QC Criteria

April 14, 2026

First Posted (Actual)

April 20, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 2, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • IDE574-001
  • 178299 (Other Identifier: Regulatory Agency Identifier Number (s))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.